Cue Biopharma Statistics

Total Valuation

Cue Biopharma has a market cap or net worth of $40.55 million. The enterprise value is $21.22 million.

Market Cap	40.55M
Enterprise Value	21.22M

Important Dates

The next estimated earnings date is Wednesday, May 13, 2026, after market close.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Cue Biopharma has 3.26 million shares outstanding. The number of shares has increased by 68.18% in one year.

Current Share Class	3.26M
Shares Outstanding	3.26M
Shares Change (YoY)	+68.18%
Shares Change (QoQ)	+9.56%
Owned by Insiders (%)	0.60%
Owned by Institutions (%)	22.31%
Float	3.24M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.65
Forward PS	4.48
PB Ratio	2.18
P/TBV Ratio	1.71
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.77
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.74, with a Debt / Equity ratio of 0.16.

Current Ratio	2.74
Quick Ratio	2.64
Debt / Equity	0.16
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-74.29

Financial Efficiency

Return on equity (ROE) is -121.11% and return on invested capital (ROIC) is -58.16%.

Return on Equity (ROE)	-121.11%
Return on Assets (ROA)	-44.56%
Return on Invested Capital (ROIC)	-58.16%
Return on Capital Employed (ROCE)	-92.35%
Weighted Average Cost of Capital (WACC)	12.40%
Revenue Per Employee	$947,103
Profits Per Employee	-$917,310
Employee Count	29
Asset Turnover	0.74
Inventory Turnover	n/a

Taxes

In the past 12 months, Cue Biopharma has paid $500,000 in taxes.

Income Tax	500,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.25% in the last 52 weeks. The beta is 1.58, so Cue Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.58
52-Week Price Change	-45.25%
50-Day Moving Average	10.58
200-Day Moving Average	16.70
Relative Strength Index (RSI)	48.34
Average Volume (20 Days)	951,824

Short Selling Information

Short Interest	7.54M
Short Previous Month	2.66M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.34

Income Statement

In the last 12 months, Cue Biopharma had revenue of $27.47 million and -$26.60 million in losses. Loss per share was -$8.42.

Revenue	27.47M
Gross Profit	-7.38M
Operating Income	-26.52M
Pretax Income	-26.10M
Net Income	-26.60M
EBITDA	-25.56M
EBIT	-26.52M
Loss Per Share	-$8.42

Full Income Statement

Balance Sheet

The company has $28.23 million in cash and $4.20 million in debt, giving a net cash position of $24.03 million or $7.38 per share.

Cash & Cash Equivalents	28.23M
Total Debt	4.20M
Net Cash	24.03M
Net Cash Per Share	$7.38
Equity (Book Value)	26.43M
Book Value Per Share	8.21
Working Capital	23.49M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$21.69 million and capital expenditures -$177,000, giving a free cash flow of -$21.86 million.

Operating Cash Flow	-21.69M
Capital Expenditures	-177,000
Depreciation & Amortization	958,000
Net Borrowing	-4.50M
Free Cash Flow	-21.86M
FCF Per Share	-$6.72

Full Cash Flow Statement

Margins

Gross margin is -26.86%, with operating and profit margins of -96.56% and -96.85%.

Gross Margin	-26.86%
Operating Margin	-96.56%
Pretax Margin	-95.03%
Profit Margin	-96.85%
EBITDA Margin	-93.07%
EBIT Margin	-96.56%
FCF Margin	n/a

Dividends & Yields

Cue Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-68.18%
Shareholder Yield	-68.18%
Earnings Yield	-58.79%
FCF Yield	-48.32%

Analyst Forecast

The average price target for Cue Biopharma is $120.00, which is 863.47% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$120.00
Price Target Difference	863.47%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	17.36%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on April 24, 2026. It was a reverse split with a ratio of 1:30.

Last Split Date	Apr 24, 2026
Split Type	Reverse
Split Ratio	1:30

Scores

Cue Biopharma has an Altman Z-Score of -10.72 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.72
Piotroski F-Score	4